155 completed, 46 recruiting, 42 unknown, 39 terminated. 165 Phase 2, 124 Phase 1, 23 Not applicable, 16 Phase 3, 2 Early Phase 1.
Follow Mesothelioma, Malignant: new trials by email Literature Review of Mesothelioma, Malignant trials Research Report on Mesothelioma, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial in Advanced Epithelioid Mesothelioma VT3989, gemcitabine, Vinorelbine - Pleural Mesothelioma, Mesothelioma | Phase 3 | Not yet recruiting | Vivace Therapeutics, Inc | 350 | 2026-12-01 | 2026-09-17 |
| Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 78 | 2026-11-01 | 2026-10-21 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | David Bartlett, MD | 10 | 2026-06-03 | 2026-08-04 |
| Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 10 | 2026-05-01 | 2026-04-07 |
| Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Cemiplimab, Fianlimab, Pemetrexed (Alimta) - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 126 | 2026-04-02 | 2026-08-11 |
| Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology Blood and Tissue Collection - Small Cell Lung Cancer, Head and Neck Cancer | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-04-01 | 2026-04-24 | |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma alrizomadlin - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-03-16 | 2026-03-17 | |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide - Malignant Pleural Mesotheliomas | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-06 |
| Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors TYK-01054 - Solid Tumor Malignancies, Malignant Mesothelioma (MM) | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 219 | 2026-01-01 | 2025-12-22 |
| Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma Partial Pleurectomy - Mesothelioma, Mesothelioma; Lung | Not applicable | Recruiting | University of Chicago | 30 | 2025-12-02 | 2026-02-17 |
| Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy - Malignant Mesothelioma, Mesothelioma | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Center, China | 55 | 2025-09-01 | 2025-08-20 |
| NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study Neoadjuvant chemo-immunotherapy, Extended pleurectomy/decortication in case of reaching operability - Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura | Phase 1 / Phase 2 | Recruiting | University Hospital, Antwerp | 37 | 2025-07-22 | 2025-08-13 |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy Ivonescimab - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 38 | 2025-06-30 | 2026-08-10 |
| OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition OT-101 - Malignant Pleural Mesothelioma | Phase 2 | Not yet recruiting | Oncotelic Inc. | 63 | 2025-06-01 | 2024-03-15 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 70 | 2025-03-31 | 2026-06-12 |
| Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 | Active not recruiting | Ruijin Hospital | 9 | 2025-03-12 | 2026-10-21 |
Showing 20 of 329. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (59) · Mesothelioma (59) · Lung Neoplasms (28) · Neoplasms (26) · Ovarian Neoplasms (23) · Pancreatic Neoplasms (23) · Solitary Fibrous Tumor, Pleural (23) · Esophageal Neoplasms (22) · Small Cell Lung Carcinoma (21) · Carcinoma, Renal Cell (19) · Colorectal Neoplasms (19) · Stomach Neoplasms (19) · Breast Neoplasms (18) · Uterine Cervical Neoplasms (18)
Neoplasms, Glandular and Epithelial (329) · Respiratory Tract Diseases (329) · Respiratory Tract Neoplasms (329) · Adenoma (328) · Lung Diseases (328) · Neoplasms by Histologic Type (328) · Neoplasms by Site (328) · Neoplasms, Mesothelial (328) · Thoracic Neoplasms (328) · Pleural Neoplasms (327) · Neoplasms (303) · Lung Neoplasms (301) · Mesothelioma (270) · Bronchial Neoplasms (65) · Carcinoma, Bronchogenic (63)
Cisplatin (57) · Pemetrexed (46) · pembrolizumab (18) · Carboplatin (15) · Gemcitabine (15) · Nivolumab (15) · Cyclophosphamide (13) · Drug Therapy (11) · Radiotherapy (10) · atezolizumab (8) · Doxorubicin (7) · Ipilimumab (7) · Platinum (7) · 1,2-diaminocyclohexaneplatinum II citrate (6) · Vinorelbine (6)
National Cancer Institute (NCI) (32) · Memorial Sloan Kettering Cancer Center (15) · M.D. Anderson Cancer Center (9) · Alliance for Clinical Trials in Oncology (7) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Ain Shams University (6) · Swiss Cancer Institute (5) · University of Chicago (5) · Abramson Cancer Center at Penn Medicine (4) · Istituto Clinico Humanitas (4) · The Netherlands Cancer Institute (4) · University Health Network, Toronto (4) · University Hospital, Antwerp (4) · AGC Biologics S.p.A. (3) · Armando Santoro, MD (3)
United States (162) · Italy (44) · United Kingdom (38) · France (28) · Netherlands (21) · Australia (19) · Belgium (19) · Canada (19) · China (19) · Spain (15) · Germany (14) · Switzerland (14) · Poland (13) · Egypt (10) · Japan (9)
David S Schrump, M.D. (8) · Armando Santoro, MD (4) · Hedy Kindler (4) · Anne S Tsao (3) · Antonio Lambiase, MD (3) · David J. Sugarbaker, MD (3) · Michael Offin, MD (3) · Andreas Rimner, MD (2) · Anne S. Tsao, MD (2) · Arkadiusz Dudek, MD (2) · Charles L. Wiseman, MD, FACP (2) · David S. Schrump, MD (2) · Dean Fennell (2)
PMID 31576173, PMID 33358660, PMID 34499875, PMID 37279993, PMID 10500494, PMID 11165136, PMID 11487589, PMID 12565988, PMID 15084390, PMID 16192580, PMID 16446322, PMID 16554548, PMID 17295916, PMID 17395581, PMID 17429100, PMID 18006112, PMID 18089874, PMID 18224661, PMID 18486741, PMID 18797818, PMID 19360120, PMID 19556318, PMID 19564349, PMID 19652065, PMID 19671873, PMID 20068553, PMID 20167848, PMID 20400682, PMID 20406925, PMID 20525721, PMID 20530048, PMID 20549206, PMID 20615924, PMID 20647340, PMID 21135147, PMID 21149657, PMID 21262916, PMID 21467219, PMID 21632857, PMID 21642245, PMID 21684151, PMID 21874000, PMID 22065672, PMID 22197613, PMID 22353806, PMID 22480131, PMID 22831987, PMID 23006802, PMID 23032745, PMID 23248097
U10CA031946 (8), 2023 (5), U10CA032102 (5), 2017 (3), P30CA014599 (3), 2008 (2), 2009 (2), N01CM17102 (2), P01CA066726 (2), P30CA016672 (2), P30CA022453 (2), P30CA043703 (2), U10CA021115 (2), U10CA180868 (2), U10CA180888 (2)